MELBOURNE, Australia, May 21, 2014 (GLOBE NEWSWIRE) -- Propanc Health Group Corporation (OTCQB:PPCH) ("Propanc Health Group", "Propanc" or "the Company"), a developmental stage healthcare company focused on new cancer treatments for patients with solid tumors, announced requests for information regarding the anti-cancer effects of its pancreatic proenzymes treatment ("PRP"), can be accessed via Cellular Oncology, a peer reviewed journal of the International Society for Cellular Oncology.
"We have received queries regarding the anti-cancer effects and mechanism of action of proenzymes, which we published last year in collaboration with our research partners," said James Nathanielsz, Chief Executive Officer of Propanc Health Group, "Publishing these findings was an important step to gain credibility within the scientific community who recognize the potential of pancreatic proenzymes as a treatment for metastatic cancer."
Propanc Health Group and its research partners identified that pancreatic proenzymes are able to suppress a long-silent, embryonic program reactivated by cancer cells, called the Epithelial Mesenchymal Transition, or EMT, by returning cancer cells back towards normal behavior. This is important because certain cancer cells develop traits such as motility, invasiveness and a resistance to readily dying. They also become "stem-cell" like and develop the ability to seed new tumors. This process, called metastasis, is responsible for approximately 90% of deaths from cancer.
"From our research we observed that pancreatic proenzymes enforce the re-entry of cancer cells into normal cellular pathways and as such, could represent an exciting new method of managing the disease process," said Dr Julian Kenyon, Chief Scientific Officer of Propanc Health Group, "We believe this small but significant step supports my initial observations from clinical practice that pancreatic proenzymes have the potential to prolong life and stop tumors from spreading, especially if we treat patients during earlier stages of the disease process".
It is anticipated a number of companies developing cancer stem cell therapies will be presenting at the upcoming 2014 ASCO (American Society of Clinical Oncologists) conference. New effective therapies against cancer stem cells attract significant attention due to their potential to control and inhibit metastatic cancer, an area where most cancer drugs often fail.
Propanc Health Group shares a joint intellectual property ownership arrangement with its research partner, the University of Bath, and patents are currently being prosecuted in countries around the world.
Propanc Health Group further aims to fast track the development of proenzyme related oncology products into clinical trials, initially for colorectal and pancreatic tumors. The world market for colorectal cancer is expected to reach $8.8 billion by 2020 and the global pancreatic cancer market is projected to exceed $1.6 billion by 2017, according to research reports.
The Company's scientific publication can be sourced from Cellular Oncology, July 2013, volume 36 (Issue 4), or purchased via the following link: http://link.springer.com/article/10.1007%2Fs13402-013-0134-8.
About Propanc Health Group Corporation
Propanc Health Group Corporation is a development stage healthcare company whose current focus is the development of new cancer treatments for patients with solid tumors such as pancreatic and colorectal cancer. Propanc, together with its scientific and oncology consultants, has developed a rational, composite formulation of anti-cancer compounds which together exert a number of anti-cancer actions. Propanc's leading products are novel, patented formulations based on proenzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects, Propanc intends to progress their lead product along the rigorous, formal non-clinical and clinical development pathway required to obtain regulatory approval to market its proenzyme formulation. Propanc intends to undertake development of manufacturing, formal non-clinical studies and then Phase I, II and III clinical trials in order to generate the quality, safety and efficacy data required for regulatory approval. For more information, please visit: www.propanc.com.
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the company's ability to implement its long range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See the company's most recent Quarterly Report on Form 10-Q and related 8K filings.
CONTACT: Propanc Health Group Corporation James Nathanielsz, Chief Executive Officer Tel: +613-9614-2795 Email: firstname.lastname@example.org Web: www.propanc.comSource: Propanc Health Group Corporation
Released May 21, 2014